Trial Profile

Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients With ventiLatory Support (ESSENTIAL) A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nangibotide (Primary)
Indications Inflammation; SARS-CoV-2 acute respiratory disease
Focus Adverse reactions; Therapeutic Use
Acronyms ESSENTIAL
Sponsors Inotrem

Most Recent Events

21 Oct 2023 This trial has been discontinued in Spain according to European Clinical Trials Database record.
01 Jun 2023 Results presented in the Inotrem Media Release.
01 Jun 2023 According to an Inotrem media release, results from this study were published in the Lancet Respiratory Medicine.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com